

Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1-36. (canceled)

37. (currently amended) A composition of matter comprising as an admixture at least one compound selected from group (i) and at least one compound selected from group (ii),

wherein group (i) consists of:

Group a) consisting of:


tramadol, O-demethyltramadol or O-demethyl-N-mono-demethyl-tramadol,

Group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- tramadol
- viminol
- butorphanol
- dextromoramide
- dezocine
- diacetylmorphine (heroin)

- hydrocodone
- hydromorphone
- ketobemidone
- levomethadone
- levomethadyl-acetate (l- α -acetylmethadol (LAAM))
- levorphanol
- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanil
- sufentanil

Group c) consisting of: ☐ 1-phenyl-3-dimethylamino-propane compounds
corresponding to formula I




wherein

X is chosen from OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from
C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated,
unsubstituted or mono- or polysubstituted,

R^1 is chosen from C_{1-4} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,
 R^2 and R^3 in each case independently of one another are chosen from H or C_{1-4} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, or
 R^2 and R^3 together form a saturated C_{4-7} -cycloalkyl radical, unsubstituted or mono- or polysubstituted,
 R^9 to R^{13} in each case independently of one another are chosen from H, F, Cl, Br, I, CH_2F , CHF_2 , CF_3 , OH, SH, OR^{14} , OCF_3 , SR^{14} , $NR^{17}R^{18}$, $SOCH_3$, $SOCF_3$; SO_2CH_3 , SO_2CF_3 , CN, $COOR^{14}$, NO_2 , $CONR^{17}R^{18}$; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;
where R^{14} is chosen from C_{1-6} -alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; $PO(O-C_{1-4}\text{-alkyl})_2$, $CO(OC_{1-5}\text{-alkyl})$, $CONH-C_6H_4-(C_{1-3}\text{-alkyl})$, $CO(C_{1-5}\text{-alkyl})$, $CO-CHR^{17}-NHR^{18}$, $CO-C_6H_4-R^{15}$, where R^{15} is ortho- $OCOC_{1-3}$ -alkyl or meta- or para- $CH_2N(R^{16})_2$ where R^{16} is C_{1-4} -alkyl or 4-morpholino, wherein in the radicals R^{14} , R^{15} and R^{16} the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;
where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or
 R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group d) consisting of [[:]] substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds corresponding to formula II



II

wherein

X is chosen from OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,


R¹ is chosen from C₁₋₄-alkyl, benzyl, CF₃, OH, OCH₂-C₆H₅, O-C₁₋₄-alkyl, Cl or F and

R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl

groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group e) consisting of $[[\cdot]]$ 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

X is chosen from OH, F, Cl, H or $OC(O)R^7$, where R^7 is chosen from C_{1-3} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and

R^9 to R^{13} in each case independently of one another are chosen from H, F, Cl, Br, I, CH_2F , CHF_2 , CF_3 , OH, SH, OR^{14} , OCF_3 , SR^{14} , $NR^{17}R^{18}$, $SOCH_3$, $SOCF_3$; SO_2CH_3 , SO_2CF_3 , CN, $COOR^{14}$, NO_2 , $CONR^{17}R^{18}$; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R^{14} is chosen from C_{1-6} -alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; $PO(O-C_{1-4}$ -alkyl)₂, $CO(OC_{1-5}$ -alkyl), $CONH-C_6H_4-(C_{1-3}$ -alkyl), $CO(C_{1-5}$ -alkyl), $CO-CHR^{17}-NHR^{18}$, $CO-C_6H_4-R^{15}$, where R^{15} is ortho- $OCOC_{1-3}$ -alkyl or meta- or para- $CH_2N(R^{16})_2$ where R^{16} is C_{1-4} -alkyl or 4-morpholino, wherein in the radicals R^{14} , R^{15} and R^{16} the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

with the proviso that if R^9 , R^{11} and R^{13} correspond to H and one of R^{10} or R^{12} corresponds to H and the other corresponds to OCH_3 , X may not be OH, and

wherein group (ii) consists of $[[:]$ an anti-muscarine agent selected from the group consisting of $[[:]$ atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and α,α -diphenylacetic acid 4-(N-methylpiperidyl) ester, as well as duloxetine, imipramine and desmopressin, or a salt of any of the foregoing with a physiologically tolerated acid.

38. (currently amended) The composition of matter of claim $[[36]]$ 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a free base.

39. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a pure enantiomer or pure diastereoisomer.

40. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a mixture of stereoisomers.

41. (currently amended) The composition of matter of claim ~~[[36]]~~ 40, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a racemic mixture.

42-43. (canceled)

44. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group a) consisting of ~~[[:]]~~ tramadol, (+)-O-demethyltramadol and (+)-O-demethyl-N-mono-demethyl-tramadol.

45. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is (+)-tramadol.

46. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group b) consisting of:

- codeine

- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- viminol
- butorphanol
- dezocine
- nalorphine
- pentazocine, and
- buprenorphine.

47. (currently amended) The composition of matter of claim ~~[[36]]~~ 46, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- meptazinol
- nalbuphine
- tilidine, and
- buprenorphine.

48. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ ~~[[or]]~~ and H, ~~[[or]]~~

R¹ is chosen from C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; [[or]]

R² and R³ independently of one another are chosen from the group consisting of H, and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; or R² and R³ together form a C₅₋₆-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted, [[or]]

R⁹ to R¹³, ~~where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H,~~ are independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃ [[or]] and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from [[:]] the group consisting of Cl, F, OH, CF₂H, CF₃, OR¹⁴ [[or]] and SR¹⁴, or

if R⁹ and R¹³ correspond to H, and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F, or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from the group consisting of OH, OC₂H₅ [[or]] and OC₃H₇.

49. (currently amended) The composition of matter of claim [[36]] 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein [[:]] X is chosen from the group consisting of OH, F, OC(O)CH₃ [[or]] and H.

50. (currently amended) The composition of matter of claim [[36]] 37, wherein said at least one compound selected from group (i) is selected from the group of

compounds corresponding to formula I wherein ~~[[:]]~~ R¹ is ~~chosen from~~ CH₃, C₂H₅, C₄H₉ or t-butyl.


51. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R² and R³ independently of one another are chosen from the group consisting of H, CH₃, C₂H₅, i-propyl ~~[[or]]~~ and t-butyl.

52. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R² and R³ together form a C₅₋₆-cycloalkyl radical which is saturated and unsubstituted.

53. (currently amended) The composition of matter of claim ~~[[36]]~~ 52, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R² and R³ together form a cyclohexyl group.

54. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R⁹ to R¹³ ~~, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H,~~ independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃, OCH₃ ~~[[or]]~~ and SCH₃; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H.

55. (currently amended) The composition of matter of claim ~~[[47]]~~ 48, wherein compounds corresponding to formula I where R³ = H are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer₁ or are provided as a pure diastereomer₁ or compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

56. (currently amended) The composition of matter of claim [[47]] 48, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

57. (currently amended) The composition of matter of claim [[47]] 48, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,
- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,

- (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
 - (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
 - (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
 - (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
 - (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, and
 - (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,
- [[or]] and hydrochloride salt of any salts of the foregoing.

58. (currently amended) The composition of matter of claim [[36]] 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula II wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ [[or]] and H, [[or]]

R¹ is ~~chosen from~~ C₁₋₄-alkyl, CF₃, OH, O-C₁₋₄-alkyl, Cl or F, [[or]]

R⁹ to R¹³, ~~where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H,~~

independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃ [[or]] and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from ~~[[:]]~~ the group consisting of Cl, F, OH, CF₂H, CF₃, OR¹⁴ ~~[[or]]~~ and SR¹⁴, or

if R⁹ and R¹³ correspond to H, and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is ~~chosen from~~ CF₃, CF₂H, Cl or F, or
if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is ~~chosen from~~ OH, OC₂H₅ or OC₃H₇.

59. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein ~~[[:]]~~ X is ~~chosen from~~ OH, F or H.

60. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein ~~[[:]]~~ R¹ is ~~chosen from~~ OH, CF₃ or CH₃.


61. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

~~R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H,~~

independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃, OCH₃ or SCH₃, with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is ~~chosen from~~ OH, CF₂H, OR¹⁴ or SCH₃.

62. (currently amended) The composition of matter of claim [[57]] 58, wherein the compounds corresponding to formula II are in the form of diastereomers corresponding to formula IIa



IIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula II are provided in the form of the (+)-enantiomer.

63. (currently amended) The composition of matter of claim [[57]] 58, wherein compounds corresponding to formula II are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

64. (currently amended) The composition of matter of claim [[57]] 58, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol,
- (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methyl-cyclohexyl)-phenol, and
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethyl-cyclohexyl)-phenol,

[[or a]] and hydrochloride salt of any salts of the foregoing.

65. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula III wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ ~~[[or]]~~ and H, ~~[[or]]~~ R⁹ to R¹³, ~~where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H,~~

independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃ ~~[[or]]~~ C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ ~~[[or]]~~ and SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is ~~chosen from~~ Cl, F, OH, SH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or


if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is ~~chosen from~~ CF₃, CF₂H, Cl or F, or
if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is ~~chosen from~~ OH, OC₂H₅ or OC₃H₇.

66. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein ~~[[:]]~~ X is ~~chosen from~~ OH, F or H.

67. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

~~R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H,~~
independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃, OCH₃ ~~[[or]]~~ and SCH₃, with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or
if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is ~~chosen from~~ OH, CF₂H, OR¹⁴ or SCH₃.

68. (currently amended) The composition of matter of claim ~~[[64]]~~ 65, wherein the compounds corresponding to formula III are in the form of diastereomers corresponding to formula IIIa



IIIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula III are provided in the form of the (+)-enantiomer.

69. (currently amended) The composition of matter of claim ~~[[64]]~~ 65, wherein compounds corresponding to formula III, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

70. (currently amended) The composition of matter of claim ~~[[64]]~~ 65, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (+)-(1R,2R)-3-(2-dimethylaminomethyl-1-fluoro-cyclohexyl)-phenol,
 - (+)-(1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
 - (1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
 - (-)-(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
 - (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
 - (-)-(1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, and
 - (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine,
- ~~[[or a]]~~ and hydrochloride salt of any salts of the foregoing.

71. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: darifenacin, duloxetine, oxybutinin and tolterodine.

72. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: oxybutinin and tolterodine.

73. (currently amended) A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim ~~[[36]]~~ 37 and ~~suitable additives or auxiliary substances~~ at least one pharmaceutically suitable additive or auxiliary substance.